High rate of lymphoma patients respond to Bristol-Myers drug-study

December 6, 2014 6:01 PM

1 0

Dec 6 (Reuters) - Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

The study of Bristol-Myers' immunotherapy drug nivolumab involved 23 patients whose lymphoma had progressed after numerous prior treatments, including chemotherapy, stem cell transplants and the Seattle Genetics drug Adcetris.

Read more

To category page